Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Debt
Short-term and long-term borrowings combined.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Debt · Q3 FY2026 · quarter ended Mar 2026
Total debt falls 8.7% from a year ago
Total debt stood at $876K at the end of Q3 FY2026, down 8.7% from a year earlier and down 11.2% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Total debt amounted to 0.5% of total assets at the end of Q3 FY2026, down 0.4 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -8.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 849K USD
- Year-over-year change
- +198.9%
- 4-year CAGR
- +41.3%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 849K | +198.9% |
| FY2024 | 2024-06-30 | 284K | -49.2% |
| FY2023 | 2023-06-30 | 559K | -31.1% |
| FY2022 | 2022-06-30 | 811K | +280.8% |
| FY2021 | 2021-06-30 | 213K | — |
Total Debt vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total debt of $876K is the lowest of the 10 companies compared; the peer median is $20.67M.
- Its year-over-year change of -8.7% is the 5th highest of 10, against a peer median of -11.6%.
- Total debt amounts to 0.5% of total assets for BNTC, versus a peer median of 4.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $135.72M | +25.7% | +49.7% | 861.2% | |
| Mar 2026 | $124.73M | +9.0% | +1469.9% | 45.9% | |
| Mar 2026 | $79.96M | -74.3% | +143.8% | 15.2% | |
| Mar 2026 | $33.3M | +4.6% | +73.2% | 58.5% | |
| Mar 2026 | $20.67M | -12.5% | -9.5% | 4.9% | |
| Dec 2025 | $19.76M | -11.6% | -25.0% | 3.7% | |
| Mar 2026 | $9.13M | -32.6% | +28.2% | 3.5% | |
| Mar 2026 | $3.71M | -69.2% | -38.0% | 1.7% | |
| Mar 2026 | $2.39M | +6.7% | -14.7% | 2.2% | |
| Mar 2026 | $876K | -8.7% | +1.5% | 0.5% | |
| Peer median (excluding BNTC) | $20.67M | -11.6% | +28.2% | 4.9% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.